Floatz logo

Talquetamab

Plasma Cell Leukemia

University of Leedsmonoclonal_antibodyPhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

40 Active assets in the Plasma Cell Leukemia cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BB
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 2BB
Dexasone
National Cancer Institute (NCI)
Phase 3B
Lenalidomide
National Cancer Institute (NCI)
Phase 3B
Melphalan
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Talquetamab is also rated in:

plasma cell myelomaActive
BB
Indicative · Phase 4
67 / 100
View asset →
Waldenstrom macroglobulinemiaActive
BB
Indicative · Phase 4
65 / 100
View asset →
hematopoietic and lymphoid system neoplasmActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →